Dedifferentiated Liposarcoma Clinical Trial
Official title:
A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03307616 -
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
|
Phase 2 | |
Completed |
NCT01913652 -
Ph II Cabazitaxel DD Liposarcoma
|
Phase 2 | |
Not yet recruiting |
NCT06389799 -
A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
|
Phase 2 | |
Recruiting |
NCT05886634 -
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
|
Phase 2 | |
Completed |
NCT06115681 -
Real-world Study of Dedifferentiated Liposarcoma Patients in China
|
||
Active, not recruiting |
NCT02846987 -
Study of Abemaciclib in Dedifferentiated Liposarcoma
|
Phase 2 | |
Terminated |
NCT04979442 -
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
|
Phase 3 | |
Completed |
NCT02606461 -
Selinexor in Advanced Liposarcoma
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242238 -
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
|
Phase 1 | |
Active, not recruiting |
NCT03651375 -
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
|
Phase 2 | |
Terminated |
NCT03604783 -
Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05496569 -
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
|
Phase 2 |